![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » European Commission Approves Opioid Dependence Implant
European Commission Approves Opioid Dependence Implant
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
Titan Pharmaceuticals and Molteni’s Sixmo (buprenorphine) subdermal implant for treating opioid addiction has earned European regulatory approval.
The device is now cleared in all European member states as a substitute treatment for clinically stable adults who require no more than eight milligrams of sublingual buprenorphine a day.
The subdermal implant, which delivers buprenorphine at a continuous rate for six months following insertion, received FDA approval in 2016 under the name Probuphine.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct